Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18364200 | CHEMICAL MODIFICATION OF ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF | Non-Final OA | Nautilus Subsidiary, Inc. |
| 18101772 | COMPOUNDS AND METHODS FOR TREATING CANCER | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18063604 | COMPOSITIONS AND METHODS FOR IMPROVED MESENCHYMAL STEM CELL THERAPY | Final Rejection | The Chinese University of Hong Kong |
| 18548657 | SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18189092 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17766189 | IMMUNOMODULATORY IMIDE DRUGS AS ZETA-CHAIN-ASSOCIATED PROTEIN KINASE 70 (ZAP70) AGONISTS AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 19019396 | Uses of Selonsertib in the Preparation of Drugs for the Treatment of Cancer | Final Rejection | AIR FORCE MEDICAL UNIVERSITY |
| 18252083 | IMPROVED SMALL MOLECULES | Non-Final OA | Promega Corporation |
| 18155115 | METHODS OF TREATING LEPTOMENINGEAL METASTASIS | Non-Final OA | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
| 18249920 | TREATMENT OF PUBLIC SPEAKING ANXIETY WITH AN ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST | Non-Final OA | Vanda Pharmaceuticals Inc. |
| 18731923 | ADMINISTRATION OF AURORA KINASE INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | Non-Final OA | Millennium Pharmaceuticals, Inc. |
| 18034965 | METHODS OF TREATING TUMORS AND CANCERS HAVING DYSREGULATED WNT SIGNALING PATHWAYS | Non-Final OA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18288734 | METHODS FOR TREATING AND MONITORING PARKINSON'S DISEASE | Non-Final OA | Denali Therapeutics Inc. |
| 18565708 | NOVEL DIPHENAZINE COMPOUND, AND USE THEREOF FOR PREVENTING OR TREATING CANCER OR NEUROINFLAMMATORY DISEASES | Non-Final OA | KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY |
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Final Rejection | BioTheryX, Inc. |
| 18524170 | Methods of Treating B-Cell Malignancy Using Bcl-2 Inhibitor | Non-Final OA | BeiGene Switzerland GmbH |
| 18263613 | TREATING CANCER IN PATIENT WITH PTEN INACTIVATING MUTATION | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 17958251 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | Final Rejection | EmpathBio, Inc. |
| 18548650 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Non-Final OA | Terns Pharmaceuticals, Inc. |
| 18000500 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | Non-Final OA | KSQ Therapeutics, Inc. |
| 18015439 | COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | Non-Final OA | AGENEBIO, INC. |
| 17618277 | Methods Of Treating Fabry Disease In Patients Having Renal Impairment | Final Rejection | Amicus Therapeutics, Inc. |
| 18361001 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Non-Final OA | NeuPharma, Inc |
| 18257384 | ORAL COMPOSITIONS COMPRISING KETAMINE COMBINED WITH SUBCUTANEAL OR INTRAVENOUS KETAMINE FOR USE IN THE TREATMENT, CONTROL OR PREVENTION OF DEPRESSIVE DISORDERS | Non-Final OA | NEUROCENTRX PHARMA LTD. |
| 18072314 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Non-Final OA | Twelve Therapeutics, Inc. |
| 18139692 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | Non-Final OA | RISEN (SHANGHAI) PHARMA ENG CO., LTD. |
| 18303191 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | Non-Final OA | Zevra Therapeutics, Inc. |
| 18249168 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | MYOFORTE THERAPEUTICS, INC |
| 17350521 | Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise | Final Rejection | Metabolic Technologies, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy